BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30316990)

  • 1. Polymerase-1 pathway activation in acute multiple sclerosis relapse.
    Achiron A; Zilkha-Falb R; Feldman A; Bovim M; Rozen O; Sarova-Pinhas I; Magalashvili D; Dolev M; Menascu S; Gurevich M
    Autoimmun Rev; 2018 Dec; 17(12):1235-1239. PubMed ID: 30316990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis.
    Achiron A; Feldman A; Magalashvili D; Dolev M; Gurevich M
    PLoS One; 2012; 7(10):e46871. PubMed ID: 23077530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental Autoimmune Encephalomyelitis Ameliorated by Passive Transfer of Polymerase 1-Silenced MOG35-55 Lymphatic Node Cells: Verification of a Novel Therapeutic Approach in Multiple Sclerosis.
    Zilkha-Falb R; Gurevich M; Achiron A
    Neuromolecular Med; 2017 Sep; 19(2-3):406-412. PubMed ID: 28755038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymerase I pathway inhibitor ameliorates experimental autoimmune encephalomyelitis.
    Achiron A; Mashiach R; Zilkha-Falb R; Meijler MM; Gurevich M
    J Neuroimmunol; 2013 Oct; 263(1-2):91-7. PubMed ID: 23998422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
    Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M
    Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global map of physical interactions among differentially expressed genes in multiple sclerosis relapses and remissions.
    Tuller T; Atar S; Ruppin E; Gurevich M; Achiron A
    Hum Mol Genet; 2011 Sep; 20(18):3606-19. PubMed ID: 21676896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse.
    Achiron A; Feldman A; Mandel M; Gurevich M
    Ann N Y Acad Sci; 2007 Jun; 1107():155-67. PubMed ID: 17804543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.
    De Andres C; García MI; Goicoechea H; Martínez-Ginés ML; García-Domínguez JM; Martín ML; Romero-Delgado F; Benguría A; Sanjurjo M; López-Fernández LA
    Pharmacogenomics J; 2018 Jan; 18(1):98-105. PubMed ID: 27670768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study.
    Kacperska MJ; Jastrzebski K; Tomasik B; Walenczak J; Konarska-Krol M; Glabinski A
    J Mol Neurosci; 2015 May; 56(1):154-63. PubMed ID: 25487315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.
    Veroni C; Marnetto F; Granieri L; Bertolotto A; Ballerini C; Repice AM; Schirru L; Coghe G; Cocco E; Anastasiadou E; Puopolo M; Aloisi F
    J Neuroinflammation; 2015 Jul; 12():132. PubMed ID: 26169064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis.
    Achiron A; Gurevich M; Snir Y; Segal E; Mandel M
    Clin Exp Immunol; 2007 Aug; 149(2):235-42. PubMed ID: 17488294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The switch between relapse and remission in multiple sclerosis: continuous inflammatory response balanced by Th1 suppression and neurotrophic factors.
    Gurevich M; Achiron A
    J Neuroimmunol; 2012 Nov; 252(1-2):83-8. PubMed ID: 22921736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated lysophosphatidic acid levels in the serum and cerebrospinal fluid in patients with multiple sclerosis: therapeutic response and clinical implication.
    Jiang D; Ju W; Wu X; Zhan X
    Neurol Res; 2018 May; 40(5):335-339. PubMed ID: 29557721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.
    Achiron A; Zilkha-Falb R; Mashiach R; Gurevich M
    J Neuroimmunol; 2017 Jan; 302():41-48. PubMed ID: 27908532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
    Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
    Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
    Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
    J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis.
    Orefice N; Carotenuto A; Mangone G; Bues B; Rehm R; Cerillo I; Saccà F; Calignano A; Orefice G
    J Steroid Biochem Mol Biol; 2016 May; 159():1-7. PubMed ID: 26892094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.
    Cox MB; Bowden NA; Scott RJ; Lechner-Scott J
    Mult Scler; 2013 Sep; 19(10):1268-74. PubMed ID: 23401127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Selected MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to Cognition, Depression, and Disability.
    Niwald M; Migdalska-Sęk M; Brzeziańska-Lasota E; Miller E
    J Mol Neurosci; 2017 Dec; 63(3-4):275-282. PubMed ID: 29043654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis.
    Hewes D; Tatomir A; Kruszewski AM; Rao G; Tegla CA; Ciriello J; Nguyen V; Royal W; Bever C; Rus V; Rus H
    Exp Mol Pathol; 2017 Apr; 102(2):191-197. PubMed ID: 28109694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.